Mediation analysis of time‐to‐event endpoints accounting for repeatedly measured mediators subject to time‐varying confounding
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In this article, we will present statistical methods to assess to what extent the effect of a randomised treatment (versus control) on a time‐to‐event endpoint might be explained by the effect of treatment on a mediator of interest, a variable that is measured longitudinally at planned visits throughout the trial. In particular, we will show how to identify and infer the path‐specific effect of treatment on the event time via the repeatedly measured mediator levels. The considered proposal addresses complications due to patients dying before the mediator is assessed, due to the mediator being repeatedly measured, and due to posttreatment confounding of the effect of the mediator by other mediators. We illustrate the method by an application to data from the LEADER cardiovascular outcomes trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 3×
“Setting M1 to the level M1(0,L1(1)), M2 to the level M2(0,L1(1),M1(0,L1(1)),L2(1,M1(0,L1(1)))), .”
BackgroundInfluentialIntroduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Mediation analysis with multiple mediators
VanderWeele, T., & Vansteelandt, S. (2014) · Epidemiologic Methods · doi:10.1515/em-2012-0010 · Cited by 858
Self-citationFlexible Mediation Analysis With Multiple Mediators
Steen, J., Loeys, T., Moerkerke, B., & Vansteelandt, S. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx051 · Cited by 123
Self-citationCounterfactual graphical models for longitudinal mediation analysis with unobserved confounding
Shpitser, I. (2013) · Cognitive Science · doi:10.1111/cogs.12058 · Cited by 106 · cited 4×
“In Web Appendix A, we argue that following the arguments of Shpitser6 and the recanting witness criterion,16 the path-specific effects represented by the causal diagram of Figure 1, are identified if (a) the exposure A is randomly assigned, (b) all common causes of the time-to-event outcome and the mediator at each ti…”
BackgroundMethodInfluential
Research works printed but not linked: 19
- 10.1097/00001648-199203000-00013 · DOI · Paper page
- PearlJ.Direct and indirect effects. In: Proceedings of the 17th Conference on Uncertainty in Artificial Intelligence (UAI'01);2001;Seattle WA.
- 10.1002/sim.6598 · DOI
- 10.1002/sim.7426 · DOI
- 10.1515/jci-2016-0006 · DOI
- Didelez V, 2018, Defining causal meditation with a longitudinal mediator and a survival outcome, Lifetime Data Anal, 1
- Pearl J, 2000, Causality: Models, Reasoning and Inference
- Robins JM, 2010, Causality and Psychopathology: Finding the Determinants of Disorders and Their Cures, 103
- 10.1007/s10985-006-9004-2 · DOI
- AvinC ShpitserI PearlJ.Identifiability of path‐specific effects. In: Proceedings of the 19th International Joint Conference on Artificial Intelligence;2005;Edinburgh Schotland.
- 10.1214/15-AOS1411 · DOI · Paper page
- 10.1111/rssb.12194 · DOI · Paper page
- 10.1002/sim.1203 · DOI · Paper page
- 10.1002/sim.7219 · DOI
- 10.1002/sim.4780080803 · DOI · Paper page
- 10.1093/biostatistics/kxx045 · DOI
- 10.1097/EDE.0000000000000596 · DOI · Paper page
- 10.1097/EDE.0000000000000034 · DOI · Paper page
- 10.1002/sim.2712 · DOI · Paper page
Cited by
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462
Buse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2251 · Cited by 175
“Cox methods, and a new, more complex method, termed the Vansteelandtmethod (10).”
BackgroundMethodInfluentialSelf-citationPotential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14443 · Cited by 120
Metadata
- Authors
- Vansteelandt, S., Linder, M., Vandenberghe, S., Steen, J., & Madsen, J.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2019-08-14
- Volume
- 38
- Issue
- 24
- Pages
- 4828-4840
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2967234778
- Cited by
- 70
- References
- 6
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Fonds Wetenschappelijk Onderzoek (G019317N)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.